MERCK KGAA

The 'Myositis - Pipeline Insight, 2024' report by ResearchAndMarkets.com offers insights into 18+ companies and 20+ pipeline drugs for Myositis, covering drug profiles, therapeutic assessments, and pipeline development activities.

The antibody production market, valued at US$ 15.6 Bn in 2023, is projected to reach US$ 30.7 Bn by 2031 with a CAGR of 7.8%, driven by advancements in bioprocessing, rising chronic disease prevalence, and increased R&D investments. Key segments include service type, sourcing type, application, industry vertical, and region. North America leads, while Asia-Pacific shows fastest growth. Market drivers include technological innovations and biologics approvals, while challenges include high production costs and regulatory hurdles. Trends include biosimilars, automation, personalized medicine, and sustainable bioprocessing.

The human organoids market is projected to grow from $1.19B in 2024 to $2.33B by 2029, at a CAGR of 14.4%. Funding and advancements in research drive market growth, with applications in drug toxicity, personalized medicine, and developmental biology. Pharmaceutical and biotech companies lead in end-user growth, while Asia-Pacific shows the fastest regional growth due to healthcare infrastructure investments and medical tourism.

SkyQuest projects the global healthcare analytical testing services market to reach USD 15.55 Billion by 2031, with a CAGR of 11.2% (2024-2031). Driving factors include outsourcing by pharmaceutical and medical device companies, increased clinical trials, and rising biosimilars emphasis. The COVID-19 pandemic also boosted demand.

Bionxt Solutions plans to launch a pilot clinical trial in H2 2025 comparing BNT23001, a sublingual cladribine formulation, to Mavenclad for MS treatment. The sublingual film aims to ease administration for patients with swallowing difficulties and is expected to act faster. Bionxt is working with a manufacturing partner and plans to file for clinical trial approval in Europe by mid-2025. Preclinical studies showed BNT23001 has comparable pharmacological properties to Mavenclad.

The global oncology-based in-vivo CRO market was valued at USD 1.4 billion in 2024 and is expected to grow at an 8.8% CAGR from 2025 to 2034, driven by demand for immuno-oncology therapies, advancements in in-vivo models, and growing oncology drug approvals from small biotech and pharmaceutical companies. Small firms lead in oncology drug approvals, focusing on innovative treatments like CAR-T cell therapy and monoclonal antibodies. The market is segmented by service, model, end use, and region, with preclinical testing dominating. Key trends include the rise of immunotherapies, outsourcing by biotech firms, AI integration, and strategic alliances between companies and CROs.

The global DNA polymerase market was valued at USD 137.0 Million in 2023 and is expected to reach USD 266.4 Million by 2034, driven by chronic illnesses, molecular diagnostics, and genomic research. Key applications include PCR, DNA sequencing, and genetic cloning.

The global DNA polymerase market was valued at USD 137.0 Million in 2023 and is expected to expand at a CAGR of 6.2% between 2024 and 2034, reaching USD 266.4 Million by 2034, driven by chronic illnesses, molecular diagnostics, and genomic research. DNA polymerase enzymes are crucial for PCR, DNA sequencing, and genetic cloning, playing a vital role in precision medicine and biotechnology innovations.

The Biotechnology Reagents market is projected to grow at a CAGR of 9.5% from 2022 to 2029, reaching USD 77.4 billion in 2020. Key companies profiled include Abbott Laboratories, Bio-Rad Laboratories Inc., Roche Diagnostics, and others. Recent developments include Agilent Technologies' compliance with EU IVDR regulation and CN Bio's launch of a reagent kit for NASH. Market segmentation covers types like Life Science Reagents and Analytical Reagents, and applications such as Protein Synthesis & Purification and Drug Testing. Geographical analysis highlights North America, Europe, Asia-Pacific, Middle East & Africa, and South America.

NKTR-255, an IL-15 agonist, enhanced CAR T-cell kinetics, achieving 73% complete response at 6 months in a Phase 2 study for relapsed/refractory Large B-cell Lymphoma, compared to 50% in the placebo group.